Shilpa Gupta: Glad to present our work on physician-reported 1L treatment patterns in 5 European countries
Enrique Grande, recently shared a post by Shilpa Gupta on X, adding:
“We all always say that age is just a number, but it seems that when push comes to shove, those of us who treat patients with bladder cancer do take into account the patient’s age as an important parameter to take into account. Great piece of work by Shilpa Gupta!
Warming up for ASCO24.”
Quoting Shilpa Gupta’s post:
“Glad to present our work on physician-reported 1L treatment patterns in 5 European countries.
- > 75% of patients offered systemic 1L treatment
- Advanced age (> med 74 years) was a major criteria for not offering treatment.”
Read further
Sources: Enrique Grande/X and Shilpa Gupta/X
Shilpa Gupta is the Director of Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials.
Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research lead at MD Anderson Cancer Center Madrid. Dr. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit. He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE).
